Were exposed to pesticides. We do not know what causes MGUS. There may be a link to autoimmune diseases, genetics, or environmental factors. Like multiple myeloma, MGUS starts in a type of white blood ...

There's a big spectrum with multiple myeloma and all these plasma cell problems, from something that we call monoclonal gammopathy of unclear significance, or MGUS, where you have just a few ...

2012;5(6):603-617. Further genetic events such as copy number abnormalities, mutations and epigenetic modifiers occur in both MGUS and myeloma and are required for progression to a malignant ...

Other diseases of the plasma cells may increase the risk of multiple myeloma. Monoclonal gammopathy of undetermined significance (MGUS) is a chronic health condition that causes the plasma cells ...

Recent studies have shown that most, if not all patients with myeloma, have a preceding monoclonal gammopathy of undetermined significance phase (MGUS). 1, 2 In this study, we derived and ...

The medical literature contains reports of around 130 families with two or more cases of MM, MGUS, or WM. An Icelandic family with multiple cases of MGUS, WM, and lymphoma was first described in 1978.

monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), with a subset of patients progressing from MGUS through SMM to multiple myeloma. 1 Many people with ...

New research shows that maintaining a healthy weight following a monoclonal gammopathy of undetermined significance diagnosis ...

A condition as serious as multiple myeloma is bound to have both profound ... certain markers of bone metabolism in people with monoclonal gammopathy of undetermined significance (MGUS).

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.